Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial.

导出 OA

翻译打印收藏纠错

第一作者： Kara W,Chew

第一单位： Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

作者： Kara W,Chew ^[1] ; Babafemi O,Taiwo ^[2] ; Carlee,Moser ^[3] ; Eric S,Daar ^[4] ; David Alain,Wohl ^[5] ; Justin,Ritz ^[3] ; Arzhang Cyrus,Javan ^[6] ; Jonathan Z,Li ^[7] ; William,Fischer ^[5] ; Alexander L,Greninger ^[8] ; Christoph,Bausch ^[9] ; Thomas,Luke ^[9] ; Robert,Call ^[10] ; Gene,Neytman ^[11] ; Mark J,Giganti ^[3] ; Courtney V,Fletcher ^[12] ; Michael D,Hughes ^[3] ; Joseph J,Eron ^[5] ; Judith S,Currier ^[1] ; Davey M,Smith ^[13] ; ACTIV-2/A5401 Study Team

作者单位： Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA. ^[1] Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. ^[2] Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. ^[3] Lundquist Institute, Harbor-University of California, Los Angeles Medical Center, Torrance, California, USA. ^[4] Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. ^[5] Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. ^[6] Department of Medicine, Harvard Medical School, Cambridge, Massachusetts, USA. ^[7] Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, Washington, USA. ^[8] SAB Biotherapeutics, Inc, Sioux Falls, South Dakota, USA. ^[9] Clinical Research Partners, Richmond, Virginia, USA. ^[10] Quantum Clinical Trials, Miami, Florida, USA. ^[11] Center for Drug Discovery, University of Nebraska Medical Center, Omaha, Nebraska, USA. ^[12] Department of Medicine, University of California, San Diego, La Jolla, California, USA. ^[13]

关键词 COVID-19 SAB-185 casirivimab/imdevimab outpatient treatment transchromosomic